Indeed, a phase I/Ib Study of AZD9150, antisense oligonucleotide inhibitor of STAT-3, in patients with advanced/metastatic HCC (NCT01839604) and a phase I study of OPB-111077, an oral STAT-3 inhibitor, in subjects with advanced HCC (NCT01942083) were certainly conducted, although the efficacy outcomes were limited (59). Here, STAT3 is linked to hepatocellular carcinoma.